Harmony Gold Mining Co. vs Kymera Therapeutics Inc. Common Stock — how do they compare? Harmony Gold Mining Co. trades at $16.84 (market cap $10.25B), while Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.88B). The key difference: Harmony Gold Mining Co. is the larger of the two by market cap, and Harmony Gold Mining Co. pays a 4.79% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Harmony Gold Mining Co. for 45 Days and Kymera Therapeutics Inc. Common Stock for 0 Days on average.
| HMY | KYMR | |
|---|---|---|
Market Cap | $10.25B | $8.88B |
Volume | 3,439,062 | 1,028,790 |
Sector | Basic Materials | Health |
52-Week High | $26.04 | $127.31 |
52-Week Low | $13.32 | $55.80 |
Typical Hold Time | 45 Days | 0 Days |
Enterprise Value | $10.30B | $8.27B |
Dividend Yield | 4.79% | — |
Signals from Pluang's Aura AI — not financial advice
Harmony Gold Mining (HMY) trades at $16.71, up 0.18% on the day, with a bearish technical signal despite strong fundamentals. The company reported record fiscal 2026 results with revenue reaching $99.2B and net income of $29.3B, driven by higher gold prices and copper expansion. Valuation metrics remain attractive with P/E of 5.96 and EV/EBITDA of 3.64, while profitability metrics show robust ROE of 46.23% and net margin of 29.57%.
HMY presents a compelling value opportunity with strong cash flow generation and strategic copper diversification, though technical weakness and mixed analyst sentiment (70% hold rating) suggest near-term caution. Key risks include commodity price volatility and execution of copper expansion plans, while the current valuation discount to historical levels offers potential upside for patient investors.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Harmony Gold Mining Co Ltd is a gold mining and exploration company having operations in South Africa and Papua New Guinea (PNG). Its projects include Bambanani, Joel, Masimong, Phakisa, Target 1, Tshepong, Unisel, Doornkop, and Kusasalethu. The group's segments are Tshepong Operations, Bambanani, Joel, Doornkop, Moab Khotsong, Hidden Valley, Target 1, Kusasalethu, Masimong, Unisel, and all other surface operations.
Read more on HMY →Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →